Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | HTR7 | P34969 | 5/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874621 | 0.91 | HTR7 (0.70) | ADRA1BHTR1AHTR7 | |
| SCHEMBL15105695 | 0.86 | HTR7 (0.55) | ADRA1BDRD2HTR1AHTR7ADRA1D | |
| SCHEMBL15105965 | 0.84 | HTR7 (0.59) | ADRA1BDRD2HTR1AHTR7ALDH1A1 | |
| SCHEMBL16144798 | 0.83 | DRD4 (0.55) | ADRA1BL3MBTL1DRD2HTR1AHTR7 | |
| SCHEMBL875129 | 0.78 | HTR1A (0.88) | ADRA1BDRD2DRD3HTR1AHTR7 | |
| SCHEMBL10833093 | 0.77 | ALDH1A1 (0.81) | ADRA1BDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL9615102 | 0.76 | ADRA2A (1.00) | ADRA1BDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL29468639 | 0.75 | ADRA2A (0.98) | ADRA1BDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL3624263 | 0.75 | ADRA2A (0.98) | ADRA1BDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL874587 | 0.75 | DRD2 (0.60) | DRD2DRD3ADRA2AHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169218-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2015-10-27 | — | — | US | claimed |
| EP-2619187-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMAC UTICOS S A (BR) | 2015-03-04 | — | — | EP | claimed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | claimed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | claimed |
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2021-11-04 | — | — | US | disclosed |
| US-9326984-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2016-05-03 | — | — | US | disclosed |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LAB FARMACEUTICOS SA (BR) | 2016-01-14 | — | — | US | disclosed |
| US-9169218-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2015-10-27 | — | — | US | disclosed |
| EP-2619187-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMAC UTICOS S A (BR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | disclosed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | disclosed |
| US-8735578-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2014-05-27 | — | — | US | disclosed |
| EP-2619187-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | Aché Laboratórios Farmacêuticos S.A. (BR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037634-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | ADRA1B 63/4885L3MBTL1 4770/4885DRD2 20/4885 |
| US-20160008360-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | ADRA1B 64/4885L3MBTL1 4763/4885DRD2 20/4885 |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR1A | ADRA1B 62/4885L3MBTL1 4853/4885DRD2 22/4885 |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR2C | ADRA1B 62/4885L3MBTL1 4860/4885DRD2 22/4885 |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR5A, HTR2A, HTR2C | ADRA1B 58/4885L3MBTL1 4857/4885DRD2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.